Telix (ASX:TLX) has announced that it has been jointly awarded a $4.8 million Australian Research Council grant to establish a new Industrial Transformation Research Program Hub as part of a consortium of applicants led by The University of Queensland.

Dimerix (ASX:DXB) has announced a new patent family application for its lead investigative candidate DMX-700 for the treatment of Chronic Obstructive Pulmonary Disease.

Pfizer has significantly raised its offer for Australian digital health company ResApp Health (ASX:RAP) to a price that reflects the recent findings of an independent report.

AusBiotech is delighted to reveal a ‘sneak peek’ into the AusBiotech 2022 programme, which features global thought-leaders, and pressing and emerging topics to drive the Australian biotech sector forward.

Medical Developments International (ASX:MVP) has announced a fully underwritten capital raising of $30 million.

Radiopharm Theranostics (ASX:RAD) has announced a collaboration agreement with Lantheus.

Osteopore (ASX:OSX) has announced that US-based distributor Bioplate has secured a non-exclusive agreement with MellingMedical to promote and sell its products within healthcare facilities owned or operated by the US government.

Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials.

Australia’s Cell and Gene Catalyst will move ahead, establishing its inaugural Steering Group and opening recruitment, formally signalling the important next step in advancing cell and gene accessibility in Australia.

Lumos Diagnostics (ASX:LDX) has announced its intention to close its facility in the US-state of Florida.

Proteomics International Laboratories (ASX:PIQ) has announced that a study demonstrating the clinical utility of the PromarkerD test in predicting diabetic kidney disease has been published in the journal PLOS ONE.

Australian researchers are seeking volunteers aged 40 and over living with severe emphysema for a world-first study of a novel two-stage procedure to treat the lung disease.

Molecular diagnostics company Genetic Signatures (ASX:GSS) has completed recruitment for the clinical trial of its 3base EasyScreen Enteric Protozoan Diagnostic Kit in the US.

Nominations for the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards are now open.

The Clinical Translation and Commercialisation Medtech Program will open its second round in September 2022 seeking applications from small to medium-sized enterprises.

Volpara Health Technologies (ASX:VHT) has announced the completion of the strategic review undertaken by CEO Teri Thomas and the executive management team.

Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received feedback from the US FDA following a review of the Investigational New Drug application for a new oral therapeutic targeting Campylobacter and ETEC.